Skip to content
The People's CodeSearch
Menu

21 U.S.C. § 360ee–1 · 21, 360ee–1 of the

§ 360ee–1. FDA rare neurodegenerative disease grant program

The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall award grants and contracts to public and private entities to cover the costs of research on, and development of interventions intended to prevent, diagnose, mitigate, treat, or cure, amyotrophic lateral sclerosis and other rare neurodegenerative diseases in adults and children, including costs incurred with respect to the development and critical evaluation of tools, methods, and processes—

(1) to characterize such neurodegenerative diseases and their natural history;

(2) to identify molecular targets for such neurodegenerative diseases; and

(3) to increase efficiency and productivity of clinical development of therapies, including through—

(A) the use of master protocols and adaptive and add-on clinical trial designs; and

(B) efforts to establish new or leverage existing clinical trial networks.

Where this text comes from

The public laws () that wrote and changed it, and where each is printed in the Statutes at Large ().

(Pub. L. 117–79, § 5, Dec. 23, 2021, 135 Stat. 1537.)

Notes (1)

Editorial Notes

Codification

Section was enacted as part of the Accelerating Access to Critical Therapies for ALS Act, and not as part of the Federal Food, Drug, and Cosmetic Act which comprises this chapter.

Would change this section

No bill we know of would change this section.

Versions

Each is an official edition of the Code (a ), up to date through the named.

  • Through Public Law 119-138, Current